{"id":"NCT03822377","sponsor":"Azienda Ospedaliero Universitaria di Sassari","briefTitle":"Ticagrelor Administered as Standard Tablet or Orodispersible Formulation","officialTitle":"Ticagrelor Administered as Standard Tablet or orodispersiblE foRmulation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-06-27","primaryCompletion":"2020-08-31","completion":"2020-08-31","firstPosted":"2019-01-30","resultsPosted":"2021-09-08","lastUpdate":"2021-09-08"},"enrollment":130,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"TREATMENT"},"conditions":["ST Elevation Myocardial Infarction","NSTEMI - Non-ST Segment Elevation MI"],"interventions":[{"type":"DRUG","name":"Ticagrelor orodispersible tablets","otherNames":[]},{"type":"DRUG","name":"Ticagrelor standard tablets","otherNames":[]}],"arms":[{"label":"Ticagrelor orodispersible tablets","type":"EXPERIMENTAL"},{"label":"Ticagrelor standard tablets","type":"ACTIVE_COMPARATOR"}],"summary":"Randomized clinical study evaluating superiority in platelet inhibition after administration of Ticagrelor 180 mg loading dose as an orodispersible formulation versus traditional coated tablets in patients admitted for ST elevation myocardial infarction or very high-risk non-ST elevation myocardial infarction.","primaryOutcome":{"measure":"Evaluation of Platelet Inhibition","timeFrame":"1 hour","effectByArm":[{"arm":"Ticagrelor Orodispersible Tablets","deltaMin":94,"sd":null},{"arm":"Ticagrelor Standard Tablets","deltaMin":141,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["Italy"]},"refs":{"pmids":["34266583"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":65},"commonTop":["Combined ticagrelor administration-related adverse events defined as in-hospital â‰¥2 BARC bleedings,"]}}